Compounds > plerixafor
Page last updated: 2024-08-24

plerixafor and Colorectal Neoplasms

plerixafor has been researched along with Colorectal Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Barmpounakis, P; Basu, B; Bax, L; Biasci, D; Brais, R; Connell, CM; Fearon, DT; Gale, D; Gallagher, FA; Gao, Y; Godfrey, E; Gopinathan, A; Hudecova, I; Isherwood, C; Janowitz, T; Jodrell, DI; Johnson, TI; Magiera, L; Mir, F; Pawula, M; Popa, EC; Richards, FM; Rosenfeld, N; Smoragiewicz, M; Thaventhiran, JED; Wang, Z1
Fearon, DT; Janowitz, T1
Beech, EY; Chung, E; Clark, JW; Fukumura, D; Heishi, T; Ho, WW; Huang, Y; Incio, J; Jain, RK; Jung, K; Kawaguchi, K; Kim, JK; Luster, AD; Padera, TP; Pinter, M; Rahbari, NN; Willett, CG; Yun, SH1
Arteta, B; Benedicto, A; Romayor, I1
Allgayer, H; Eckstein, V; Fruehauf, S; Giordano, FA; Heckmann, D; Laufs, S; Maier, P; Veldwijk, MR; Wenz, F; Zeller, WJ; Zucknick, M1
Li, JK; Shen, Y; Wang, YC; Yu, L; Zhang, JH; Zhou, LS1

Other Studies

6 other study(ies) available for plerixafor and Colorectal Neoplasms

ArticleYear
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 11-17, Volume: 117, Issue:46

    Topics: Aged; Benzylamines; Carcinoma, Pancreatic Ductal; Chemokine CXCL12; Colorectal Neoplasms; Cyclams; Female; Heterocyclic Compounds; Humans; Immunity; Immunotherapy; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Receptors, CCR2; Receptors, CXCR3; Receptors, CXCR4; Receptors, CXCR5; Receptors, CXCR6; Receptors, Interleukin-8A; Signal Transduction; Tumor Microenvironment

2020
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
    British journal of cancer, 2021, Volume: 125, Issue:2

    Topics: Benzylamines; Chemokine CXCL12; Colorectal Neoplasms; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Pancreatic Neoplasms; Receptors, CXCR4

2021
Targeting CXCR4-dependent immunosuppressive Ly6C
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 09-26, Volume: 114, Issue:39

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Ly; Benzylamines; Bevacizumab; Cell Proliferation; Chemokine CXCL12; Colorectal Neoplasms; Cyclams; Heterocyclic Compounds; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Neutrophils; Ramucirumab; Receptors, CXCR4; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2017
CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
    Oncology reports, 2018, Volume: 39, Issue:4

    Topics: Animals; Benzylamines; Cancer-Associated Fibroblasts; Cell Movement; Cell Proliferation; Chemokine CXCL12; Colorectal Neoplasms; Cyclams; Gene Expression Regulation, Neoplastic; Hepatic Stellate Cells; Heterocyclic Compounds; Humans; Liver Neoplasms; Mice; Receptors, CXCR4; Signal Transduction; Stromal Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays

2018
A Lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1α-induced migration and invasion.
    Onkologie, 2011, Volume: 34, Issue:10

    Topics: Anti-HIV Agents; Benzylamines; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Colorectal Neoplasms; Cyclams; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Vectors; Heterocyclic Compounds; Humans; Lentivirus; Neoplasm Invasiveness; Receptor Cross-Talk; Receptors, CXCR4

2011
Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
    World journal of gastroenterology, 2008, Apr-21, Volume: 14, Issue:15

    Topics: Antineoplastic Agents; Benzylamines; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Colorectal Neoplasms; Cyclams; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A

2008